Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IM Cannabis Corp C.IMCC

Alternate Symbol(s):  IMCC

IM Cannabis Corp. is a Canada-based international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel. In Germany, the Company operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. It offers four different product lines, leading with the Craft Collection which offers the highest quality Canadian craft cannabis flower. The Company's other product lines include Top-Shelf Collection, Signature Collection and Full Spectrum Extracts. The Company's brands include The WAGNERS, BLKMKT, LOT420, and The PICO collection (minis).


CSE:IMCC - Post by User

Post by RockMaschineon Mar 29, 2022 12:07pm
222 Views
Post# 34555674

$20 million incoming Q4

$20 million incoming Q4
dont know why news has not been widely distributed. Middle of March they pre announced in excess of $20 million Q4 and $54 million on the year. Have also released news about closing all previous transactions along with Israel medical board approval for the pharmacy acquisition. Should set up well if there is a return of better sentiment in the rest of the sector. I'll just continue to buy waiting on the big news out of Germany. Earnings call is listed for tomorrow but year end wont come out until end of April.
<< Previous
Bullboard Posts
Next >>